期刊
HEART
卷 96, 期 23, 页码 1872-1877出版社
B M J PUBLISHING GROUP
DOI: 10.1136/hrt.2009.180430
关键词
-
资金
- British Heart Foundation [RG/07/003/23133, PG/08/119/26263]
- NIHR Oxford Biomedical Research Centre
- BioMarin Pharmaceutical Inc. [NCT00423280]
- British Heart Foundation [RG/07/003/23133] Funding Source: researchfish
- National Institute for Health Research [NF-SI-0508-10247] Funding Source: researchfish
Tetrahydrobiopterin (BH4) functions as a cofactor in several important enzyme systems. Substantial evidence implicates BH4 as a key regulator of endothelial nitric oxide synthase (eNOS) in the setting of endothelial dysfunction and atherosclerosis. Investigators have now taken early steps in addressing the potential of BH4 as a therapeutic strategy. However, it has become more apparent that the role of BH4 in other enzymatic pathways, including other NOS isoforms and the aromatic amino acid hydroxylases, may have a bearing on important aspects of cardiovascular homeostasis. Together with eNOS, these enzymes may play key roles in diverse cardiovascular disease states such as ischaemia-reperfusion injury, cardiac hypertrophy, cardiac autonomic function and pulmonary hypertension. This review provides an overview of the role of BH4 in cardiovascular pathophysiology.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据